Fortis Life Sciences Company Profile

Background

Founded in August 2020, Fortis Life Sciences is a strategic platform company headquartered in Waltham, Massachusetts. The company is dedicated to supporting the growth and success of founder-led life science tools companies by providing capital, expertise, and operational resources. Fortis aims to offer world-class products coupled with a best-in-class customer experience, serving a global customer base across biopharma, diagnostics, academic research, government, and applied industries.

Key Strategic Focus

Fortis Life Sciences focuses on accelerating scientific discovery through a comprehensive portfolio of products and services. The company's core objectives include:

Premium Portfolio: Developing and validating in-house products backed by rigorous quality controls to advance research and clinical success.

Custom Solutions: Designing and manufacturing reagents and components customized to customers' exact specifications for optimized performance.

High-Impact Expertise: Employing a team of biologists, chemists, and manufacturing experts to collaborate with customers in developing and scaling life-changing breakthroughs.

Fortis serves over 500 biopharma, diagnostics, research, and applied technology customers globally, with a presence in five North American manufacturing and R&D locations, including three ISO 13485 and GMP certified sites.

Financials and Funding

While specific financial details are not publicly disclosed, Fortis Life Sciences has demonstrated strong financial performance since its inception. The company has expanded its commercial capabilities significantly, building a portfolio of high-quality products and brands serving diagnostic, therapeutic, and discovery markets. Fortis was founded in collaboration with global growth equity investor Summit Partners, addressing a significant gap in the life science tools market.

Pipeline Development

Fortis Life Sciences has expanded its capabilities through strategic acquisitions, enhancing its product offerings and services:

Bethyl Laboratories: Manufactures premium quality, proprietary antibodies, and custom antibody services for the life sciences industry.

nanoComposix: Specializes in ultra-sensitive, quantitative lateral flow diagnostic assays, producing nanoparticles and offering custom assay development and contract manufacturing services.

Empirical Bioscience: Produces assay-grade molecular biology enzymes exclusively for diagnostic and commercial assay customers.

Arista Biologicals: Manufactures antibodies and other immunodiagnostic reagents for rapid testing assays used in drugs of abuse, infectious diseases, and fertility testing.

Abcore: Specializes in single-domain antibody technology, extending Fortis' capabilities into the antibody discovery market serving biopharma customers developing antibody and VHH-based therapeutics.

International Point of Care (IPOC): Develops and manufactures key components used in diagnostics, including lyophilized reagents, membranes, recombinant proteins, and controls.

Vector Biolabs: Offers both catalog and comprehensive end-to-end AAV and AdV solutions to support customers in viral vector design and production.

Technological Platform and Innovation

Fortis Life Sciences distinguishes itself through several proprietary technologies and scientific methodologies:

Lyophilization Services: With over 25 years of expertise in lyophilized bead technology, Fortis enhances reagent stability and eliminates cold chain requirements, producing up to 60 million beads monthly.

Blood Separation Membranes: The PrimeCare™ asymmetric membranes enable efficient blood component isolation with separation times up to 60s/cm², featuring proprietary anti-hemolytic coating for optimal sample integrity.

Control Swabs: Lyophilized control swabs provide room temperature stability for extended periods, delivering consistent dissolution and performance across lots, supporting applications from molecular diagnostics to rapid antigen detection.

Leadership Team

Fortis Life Sciences is led by a team of experienced professionals:

Brian Kim: Chief Executive Officer.

Debra Thompson: Chief People and Integration Officer.

Young K. Yun, PhD: Vice President and General Manager of APAC, leading the Fortis Korea headquarters in Seoul, Korea.

Leadership Changes

In October 2022, Fortis appointed Dr. Young K. Yun as Vice President and General Manager of APAC, establishing the regional headquarters in Seoul, Korea.

Competitor Profile

Market Insights and Dynamics

The life sciences industry is characterized by rapid innovation and significant growth potential, driven by advancements in diagnostics, therapeutics, and research tools. Companies in this sector focus on developing high-quality reagents, diagnostic assays, and custom solutions to meet the evolving needs of biopharma, diagnostics, and research markets.

Competitor Analysis

Key competitors in the life sciences tools market include:

Thermo Fisher Scientific: Offers a comprehensive range of products and services for diagnostics, life sciences research, and applied markets.

Bio-Rad Laboratories: Provides a broad array of products for life science research and clinical diagnostics.

Merck KGaA (MilliporeSigma): Delivers a wide range of innovative tools and technologies for the life science industry.

Abcam: Specializes in the production and distribution of high-quality antibodies and related products.

These competitors focus on developing and supplying high-quality reagents, diagnostic assays, and custom solutions to meet the evolving needs of biopharma, diagnostics, and research markets.

Strategic Collaborations and Partnerships

Fortis Life Sciences has engaged in significant collaborations to enhance its market position and innovation capacity:

Lunaphore: In May 2023, Fortis' subsidiary Bethyl Laboratories partnered with Lunaphore to promote compatibility and expansion of Bethyl’s library of primary antibodies on Lunaphore’s COMET™ platform.

AccuGenomics: In March 2022, Fortis partnered with AccuGenomics to expand its genomics portfolio, becoming the exclusive channel partner for AccuGenomics in the United States, with co-exclusive rights in Europe.

Operational Insights

Fortis Life Sciences differentiates itself through a combination of high-quality products, custom solutions, and a customer-first orientation. The company's strategic acquisitions have expanded its capabilities across diagnostics, therapeutics, and research discovery, enabling it to offer comprehensive solutions to its customers. Fortis' commitment to quality is underscored by its ISO 13485 certified and GMP compliant facilities, ensuring consistent and reliable product performance.

Strategic Opportunities and Future Directions

Fortis Life Sciences is poised for continued growth through:

Expansion into Emerging Markets: Establishing a presence in regions with growing demand for life science tools, such as the Asia-Pacific market.

Continued Strategic Acquisitions: Identifying and integrating complementary companies to enhance product offerings and technological capabilities.

Investment in Innovation: Developing proprietary technologies and expanding service offerings to meet the evolving needs of the life sciences industry.

By leveraging its current strengths and strategic initiatives, Fortis aims to solidify its position as a leading provider of life science tools and services.